Mannatech Antioxidant Product Receives Two New Patents

  Mannatech Antioxidant Product Receives Two New Patents

  Ambrotose AO^® capsules granted Decision to Grant for Europe and patent in
                                  Indonesia

Business Wire

COPPELL, Texas -- February 26, 2014

Mannatech, Incorporated  (NASDAQ: MTEX), the founder of the M5M^SM (Mission 5
Million^SM) social entrepreneurial movement, the pioneer of nutritional
glycobiology and the leading innovator of naturally-sourced supplements based
on Real Food Technology^® solutions, announces the issuance of two new patents
pertaining to its Ambrotose AO formulations, increasing the total patents held
by the company to more than 90.

“While the vast majority of antioxidant supplements rely on high-dose
synthetic ingredients,” said Dr. Sinnott, CEO and Chief Science Officer at
Mannatech, “we knew back in 2003 when we launched Ambrotose AO that a better
approach would be to formulate a synergistic blend of fat- and water-soluble
food-sourced antioxidant nutrients that resemble the nutrients found in a diet
rich in fresh fruits and vegetables. Proof of the benefit of Ambrotose AO
supplementation, as measured by increased serum oxygen radical antioxidant
capacity (ORAC), has been confirmed in three human clinical trials.^1,2,3 The
product’s safety has been confirmed during these studies and by 11 years of
data collected by our outstanding Safety Monitoring Program.”*

Mannatech received the Decision to Grant from the European Patent Office and
was issued the Letters Patent for Indonesia pertaining to its Ambrotose AO
formulation. More than 25 patents have been issued worldwide to Mannatech for
the technology pertaining to this formula.Overall, more than 90 patents have
been issued worldwide to Mannatech for the technology pertaining to its
Ambrotose, Ambrotose AO, GI-ProBalance^®, and PhytoMatrix^® product
formulations and in the field of biomarker assays.

“Mannatech had the foresight to begin developing its patent portfolio in the
mid-1990s,” continued Dr. Sinnott. “These two new patents are a direct result
of our systematic research and intellectual property development which has
continued without pause since the company began.”

Individuals interested in Mannatech’s products, or exploring its social
entrepreneurial efforts to help fight global malnutrition, can learn more at
Mannatech.com. Those interested in obtaining technical information and reading
published product studies may visit MannatechScience.org.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and
skin care products that are based on the solid foundation of nutritional
science and development standards. Mannatech is dedicated to its platform of
Social Entrepreneurship based on the foundation of promoting, aiding and
optimizing nutrition where it is needed most around the world. Mannatech’s
proprietary products are available through independent sales Associates around
the globe, including the United States, Canada, South Africa, Australia, New
Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the
United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of
Ireland, Czech Republic, the Republic of Korea, Mexico, Namibia, Hong Kong and
Ukraine. For more information, visit Mannatech.com.

Please note: This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E
of the Securities Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements generally can
be identified by use of phrases or terminology such as “intend” or other
similar words or the negative of such terminology. Similarly, descriptions of
Mannatech’s objectives, strategies, plans, goals or targets contained herein
are also considered forward-looking statements. Mannatech believes this
release should be read in conjunction with all of its filings with the United
States Securities and Exchange Commission and cautions its readers that these
forward-looking statements are subject to certain events, risks, uncertainties
and other factors. Some of these factors include, among others, Mannatech’s
inability to attract and retain Associates and Members, increases in
competition, litigation, regulatory changes and its planned growth into new
international markets. Although Mannatech believes that the expectations,
statements and assumptions reflected in these forward-looking statements are
reasonable, it cautions readers to always consider all of the risk factors and
any other cautionary statements carefully in evaluating each forward-looking
statement in this release, as well as those set forth in its latest Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed
with the United States Securities and Exchange Commission, including its
current reports on Form 8-K. All of the forward-looking statements contained
herein speak only as of the date of this release.

                                Reference List

1. Boyd S, Gary K, Koepke CM, et al. An open-label pilot study of the
antioxidant effect in healthy people of Ambrotose AO. GlycoScience & Nutrition
2003; 4(6): 1-6.

2. Myers SP, Stevenson L, Cheras PA, et al. A forced titration study of the
antioxidant and immunomodulatory effects of Ambrotose AO supplement. BMC Comp
Alt Med 2010; 10(16): 1-16.

3. Bloomer RJ, Canale RE, Blankenship MM, et al. Effect of Ambrotose AO on
resting and exercise-induced antioxidant capacity and oxidative stress in
healthy adults. Nutr J 2010; 9(49): 1-17.

These studies were funded by Mannatech.

*These statements have not been evaluated by the U.S. Food and Drug
Administration. These products are not intended to diagnose, treat, cure or
prevent any disease.

Contact:

Mannatech, Incorporated
Brett Duncan, 972-471-7367
bduncan@mannatech.com
 
Press spacebar to pause and continue. Press esc to stop.